CA2483218A1 - Materiaux particulaires - Google Patents

Materiaux particulaires Download PDF

Info

Publication number
CA2483218A1
CA2483218A1 CA002483218A CA2483218A CA2483218A1 CA 2483218 A1 CA2483218 A1 CA 2483218A1 CA 002483218 A CA002483218 A CA 002483218A CA 2483218 A CA2483218 A CA 2483218A CA 2483218 A1 CA2483218 A1 CA 2483218A1
Authority
CA
Canada
Prior art keywords
active substance
substance according
micronisation
granulation
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002483218A
Other languages
English (en)
Other versions
CA2483218C (fr
Inventor
Peter York
Boris Yu Shekunov
Mahboob Ur Rehman
Jane Catherine Feeley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209402A external-priority patent/GB0209402D0/en
Priority claimed from GB0210268A external-priority patent/GB0210268D0/en
Priority claimed from GB0211086A external-priority patent/GB0211086D0/en
Priority claimed from GBGB0216562.9A external-priority patent/GB0216562D0/en
Application filed by Individual filed Critical Individual
Publication of CA2483218A1 publication Critical patent/CA2483218A1/fr
Application granted granted Critical
Publication of CA2483218C publication Critical patent/CA2483218C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des substances actives se présentant sous forme particulaire, des procédés de préparation et d'utilisation de ces dernières. L'invention se rapporte à des poudres particulaires, telles que celles pouvant être utilisées pour l'apport au moyen d'un inhalateur de poudre sèche ou d'un dispositif d'apport similaire, présentant des propriétés qui peuvent être bénéfiques pour le processus d'apport de l'inhalateur de poudre sèche.
CA2483218A 2002-04-25 2003-04-24 Materiaux particulaires Expired - Lifetime CA2483218C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0209402.7 2002-04-23
GB0209402A GB0209402D0 (en) 2002-04-25 2002-04-25 Particulate materials
GB0210174A GB0210174D0 (en) 2002-04-25 2002-05-03 Particulate materials
GB0210174.9 2002-05-03
GB0210268A GB0210268D0 (en) 2002-04-25 2002-05-07 Particulate materials
GB0210268.9 2002-05-07
GB0211086.4 2002-05-15
GB0211086A GB0211086D0 (en) 2002-04-25 2002-05-15 Particulate materials
GBGB0216562.9A GB0216562D0 (en) 2002-04-25 2002-07-17 Particulate materials
GB0216562.9 2002-07-17
PCT/GB2003/001747 WO2003090715A2 (fr) 2002-04-25 2003-04-24 Materiaux particulaires

Publications (2)

Publication Number Publication Date
CA2483218A1 true CA2483218A1 (fr) 2003-11-06
CA2483218C CA2483218C (fr) 2012-07-10

Family

ID=28795261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2483218A Expired - Lifetime CA2483218C (fr) 2002-04-25 2003-04-24 Materiaux particulaires

Country Status (5)

Country Link
EP (1) EP1501483A2 (fr)
AU (1) AU2003226567A1 (fr)
CA (1) CA2483218C (fr)
GB (1) GB2387781A (fr)
WO (1) WO2003090715A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407368A (pt) * 2003-02-10 2006-02-14 Bayer Healthcare Ag tratamento de doenças bacterianas dos órgãos respiratórios mediante aplicação local e fluor-quinolonas.
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
DK2252275T3 (en) * 2008-02-13 2018-03-05 Univ Texas CREATED NON-OPEN FLOCKS OF ANISOTROPIC PARTICLES FOR IMPROVED TRANSPORT INTO THE Lungs
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
WO2014186754A2 (fr) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Vaccins contenant un adjuvant d'aluminium solide sec et procédés associés
SG11201608985QA (en) 2014-04-28 2016-11-29 Philip Morris Products Sa Flavoured nicotine powder inhaler
HUE045841T2 (hu) * 2014-04-28 2020-01-28 Philip Morris Products Sa Nikotinpor-inhalátor
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
AU2017246316B2 (en) 2016-04-04 2022-09-29 Crititech, Inc. Methods for solid tumor treatment
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CA3063436A1 (fr) 2017-06-14 2018-12-20 Crititech, Inc. Methodes de traitement de troubles pulmonaires
CA3076919A1 (fr) 2017-10-03 2019-04-11 Crititech, Inc. Administration locale de particules antineoplasiques en combinaison avec une administration systemique d'agents immunotherapeutiques pour le traitement du cancer
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
WO2021219230A1 (fr) 2020-04-30 2021-11-04 Paolo Fiorina Traitement antiviral

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
DE10129374A1 (de) * 2001-06-20 2003-01-02 Roehm Gmbh Verfahren zur Herstellung von Formkörpern mit elektrisch-leitfähiger Beschichtung und Formkörper mit entsprechender Beschichtung

Also Published As

Publication number Publication date
AU2003226567A1 (en) 2003-11-10
WO2003090715A2 (fr) 2003-11-06
CA2483218C (fr) 2012-07-10
GB2387781A8 (en) 2003-12-17
WO2003090715A3 (fr) 2004-03-11
EP1501483A2 (fr) 2005-02-02
GB2387781A (en) 2003-10-29

Similar Documents

Publication Publication Date Title
Kaialy et al. Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler
CA2483218A1 (fr) Materiaux particulaires
JP5694643B2 (ja) 改善された流動性を示す組成物
JP3011770B2 (ja) 吸入適用のための製剤
EP1007017B2 (fr) Budesonide / formoterol formulation pour inhalation ayant une masse volumique apparente de 0,30 a 0,36 g/ml, procede de preparation et utilisation de cette formulation
US6641844B1 (en) Modified carrier particles for use in dry powder inhalers
US20180055772A1 (en) Method Of Making Particles For Use In A Pharmaceutical Composition
Saint-Lorant et al. Influence of carrier on the performance of dry powder inhalers
MXPA02010218A (es) Formulaciones farmaceuticas inhaladores de polvo seco en forma de aglomerados duros.
CA2706634A1 (fr) Preparation d'agglomerats de poudre
SK286981B6 (sk) Prášok na použitie v inhalátore na suché prášky, nosič na tento prášok a spôsob výroby prášku
CA2732585A1 (fr) Formulations contenant des particules porteuses, de grande taille, destinees a des aerosols pour administration par inhalation de poudre seche
Iida et al. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier
NZ521972A (en) Improvements in or relating to formulations for use in inhaler devices
US20180235880A1 (en) Dry powder pharmaceutical compositions and methods
JP4348179B2 (ja) 安定な粉末吸入投与組成物
RU2004103187A (ru) Композиции инсулина для носового введения
CN109200034A (zh) 一种可吸入干粉形式的组合物及其制备方法
Watling et al. Entrainment of lactose inhalation powders: A study using laser diffraction
WO2009142852A2 (fr) Procédé de fabrication de compositions médicamenteuses pulvérulentes coulables
Gilani et al. Influence of formulation variables and inhalation device on the deposition profiles of cromolyn sodium dry powder aerosols
RU2338552C2 (ru) Фармацевтическая композиция для ингаляции
CA2413692C (fr) Procede permettant de produire des particules destinees a etre utilisees dans une composition pharmaceutique
US5980949A (en) Formulation for inhalation
Malamatari et al. Microcomposite particles for drug delivery to the lungs: Can they be administered as dry powders or is blending with a carrier still needed?

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230424